Mirvaso

The gel contains Brimonidine tartrate which is indicated for the symptomatic treatment of facial erythema of rosacea in adults.

Brimonidine tartrate is a highly selective alpha‑2 adrenergic receptor agonist, with potent vasoconstrictive and vasostabilising activity meaning Mirvaso reduces facial flushing and redness by reducing bloodflow to the area.

For FREE delivery by
Order within

No Hidden Costs

Prescription & delivery included

Free Next Day Delivery

On all orders before 1pm

Genuine Medication

CQC Registered Pharmacy

Brimonidine tartrate

1 gram of gel contains 3.3mg of brimonidine (equivalent to 5mg of brimonidine tartrate)

An aqueous gel which is white to light yellow in colour.

Portrait of doctor

Dosage

  • Mirvaso is applied to affected areas of the face ONCE A DAY.
  • Mirvaso is to be applied smoothly and evenly as a thin layer to affected areas
  • A small peas size amount would be the correct amount applied to each of the 5 areas ie forehead, chin, 2 cheeks and nose.
  • The maximum daily recommended dose is 1g in total weight of gel equivalent to five peas size amounts which contains 5mg of brimonidine tartrate in total.
  • Do not apply to eyes, eyelids, lips, mouth and inner nose and ensure hands are washed well after each application.
  • Not to be applied to irritated skin or open wounds.
  • For external use only.
  • Can be used at the same time as other creams and cosmetics.  These should not be applied immediately before or after the daily application of Mirvaso.  Instead the patient should wait for the applied Mirvaso gel to dry before applying any other product.


Treatments should be initiated with a smaller amount of gel for at least one week (i.e. less than the maximum amount of 1 gram).  This should then be increased gradually, according to tolerability, to the maximum daily dosage.

Warnings and precautions

For a comprehensive list please read the patient information leaflet provided with product.

Or click on the link below

https://www.medicines.org.uk/emc/files/pil.5303.pdf


Consult your GP if you fall into any of the categories below before using Mirvaso - 

 

  • Patients taking monoamine oxidase (MAO) inhibitor therapy and patients on tricyclic or tetracycline antidepressants.
  • You have problems with your heart or circulation.
  • Decreased blood flow to the hands, feet or skin,
  • Sjögren’s syndrome (a chronic disease in which the body’s natural defence - the immune system -attacks the moisture-producing glands).
  • You have kidney or liver problems or have had them in the past.
  • If you are pregnant or breastfeeding.


Mirvaso should not be used by patients under the age of 18.  Do not use if you are allergic to the active ingredient or to any of the excipients.  Discontinue treatment if you suffer from a severe reaction or contact allergy to the product.  


Do not use more than the maximum recommended daily dosage.

Side Effects

Like all medicines, Mirvaso can cause side effects, although not everyone gets them.

Common side effects:

  • Flushing
  • Whitening (pallor) where the gel is applied
  • Skin redness
  • Burning feeling of the skin or itching


Uncommon side effects

Acne, dry mouth, feeling cold in hands and feet, feeling hot, headache, nasal congestion, skin rash, skin pain or discomfort, skin irritation or inflammation, dry skin, warm skin sensation, tingling or sensation of pins and needles, swelling of the eyelid, swelling of the face, urticaria, worsening of rosacea, dizziness.


Rare side effects

Angioedema (a serious allergic reaction usually with swelling of the face, mouth or tongue). Stop treatment if this occurs, hypotension (blood pressure decreased), decreased heart rate (slow heart rate, known as bradycardia).


A full list of potential side effects can be found in the product literature and patient information leaflet.  We highly recommend all patients read this efore initiating any treatment.

Patient information leaflet 

https://www.medicines.org.uk/emc/product/5303/pil 


NHS Choices website for information on rosacea

https://www.nhs.uk/conditions/rosacea/